Ocular inflammation treatment market: Global Analysis and forecast (2023-2029)


Global Ocular inflammation treatment market is expected to reach US$ 262.02 Mn. at a CAGR of 6 during the forecast period 2029.

This is a comprehensive report analyzing the current market. The word uvea (referring to grape or grape-like), also called uveal layer or vascular tunic is the pigmented in middle of the three concentric layers that make a human eye. An inflamed ocular is a condition when uvea turns swollen, red and painful.
Ocular inflammation treatment marketTo know about the Research Methodology:-Request Free Sample Report

This condition causes irritations, burning, redness, blurred vision, sensitivity to light, irregularly shaped pupil, dark spots in vision basically and in worst cases, it causes permanent blindness.

Key Highlights:

Global market analysis and forecast, in terms of value.

Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global market

Global market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided.

The Global market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study.

Global market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation.

Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled.

Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global market are also profiled.

This study has done to provide information about the global market, related market and hence to show opportunities, major global revenue makers in this field.

The scope of the Ocular inflammation treatment market : Inquire before buying






Global Ocular Inflammation Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 174.25 Mn.




Forecast Period 2023 to 2029 CAGR:
6%
Market Size in 2029:
US $ 262.02 Mn.




 Segments Covered:
by treatment type
Anterior uveitis
Intermediate uveitis
Posterior uveitis
Pan- uveitis or Diffuse uveitis




by Type
Analgesics
Antibodies
Antifungal
Antiviral
rticosteroids
Cycloplegic agents
Immunosuppressant
Monoclonal antibodies




by uvea
Infectious
Non-infectious
Systemic disorders
Side effect of drug




by Pathophysiology
Immunological factor
Infectious factor
Genetic factor




by channel of distribution
Online channel
Retail pharmacies
Hospital pharmacies
Small drug stores
Home delivery






Ocular Inflammation Treatment Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Ocular inflammation treatment market Key Players are:

1. AbbVie Inc.
2. Alimera Sciences Inc.
3. Allergan Inc.
4. Bausch & Lomb Incorporated.
5. Eyegate
6. Eyegate Pharmaceuticals Inc.
7. Novartis AG (Alcon Laboratories Inc.)
8. pSivida Corp.
9. Regeneron Pharmaceuticals Inc.
10. Santen Pharmaceutical Co. Ltd.
11. Valeant Pharmaceuticals International Inc.
12. Akorn Pvt. Ltd
13. Roche Ltd
14. Senju Pharmaceutical Co. Ltd
15. Bayer HealthCare Pharmaceutical LLC
16. Pfizer Pharmaceutical company
17. Cipla Ltd.
18. Ocular Therapeutix, Inc.
19. Kala Pharmaceuticals
20. AxeroVision, Inc.
21. Myvision Eyeclinic
22. John Musumeci Optical Pty Ltd

Frequently Asked questions

1. What is the market size of the Global Ocular Inflammation Treatment Market in 2022?
Ans. The market size Global market in 2022 was US$ 174.25 Million.

2. What are the different segments of the Global Ocular Inflammation Treatment Market?
Ans. The Global market  is divided into treatment type, uvea, Pathophysiology and Distribution Channel.

3. What is the study period of this market?
Ans. The Global Ocular Inflammation Treatment Market will be studied from 2022 to 2029.

4. Which region is expected to hold the highest Global Ocular Inflammation Treatment Market share?
Ans. The Asia Pacific dominates the market share in the  market.

5. What  is the Forecast Period of Global Ocular Inflammation Treatment Market?
Ans. The Forecast Period of the market is 2023-2029 in the market. 




1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY
2.1. Market Definition
2.2. Market Scope
2.3. Data Sources
3. MARKET VARIABLES & SCOPE
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Market Restraint Analysis
3.4. Penetration &Growth Prospect Mapping
3.5. Market SWOT Analysis, By Factor (political & legal, economic and technological)
3.6. Porter’s Five Forces Industry Analysis
3.7. Market Value Chain Analysis
4. Ocular inflammation treatment market by region
4.1. Introduction
4.2. North America
4.3. Latin America
4.3.1.1. Brazil
4.3.1.2. Argentina
4.3.1.3. Rest of Latin America
4.4. Europe
4.4.1.1. Russia
4.5. Asia Pacific (APAC)
4.6. Middle East and Africa (MEA)
4.6.1.1. GCC Countries
4.6.1.2. Israel
4.6.1.3. Rest of Middle-east and Africa
4.7. Rest of APAC
5. Ocular inflammation treatment market by types of diseases
5.1. Introduction
5.2. Anterior uveitis
5.3. Intermediate uveitis
5.4. Posterior uveitis
5.5. Pan- uveitis or Diffuse uveitis
6. Ocular inflammation treatment market by treatment type
6.1. Introduction
6.2. Analgesics
6.3. Antibodies
6.4. Antifungal
6.5. Antiviral
6.6. Corticosteroids
6.7. Cycloplegic agents
6.8. Immunosuppressant
6.9. Monoclonal antibodies
7. Ocular inflammation treatment market by causes
7.1. Introduction
7.2. Infectious
7.3. Non-infectious
7.4. Systemic diseases
7.5. Side effect of drug
7.6. White dot syndrome
7.7. Masquerade syndrome
7.7.1.1. Neoplastic
7.7.1.2. Non-neoplastic
8. Ocular inflammation treatment market by distribution of drugs 
8.1. Introduction
8.2. Online channel
8.3. Retail pharmacies
8.4. Hospital pharmacies
8.5. Small drug stores
8.6. Home delivery
9. Ocular inflammation treatment market by key players
9.1. Introduction
9.2. AbbVie Inc.
9.2.1.1. By diseases type
9.2.1.1.1.1. Global market share
9.2.1.1.1.2. Region of operation
9.2.1.2. By treatment type
9.2.1.2.1.1. Global market share
9.2.1.2.1.2. Area of operation
9.3. Alimera Sciences Inc.
9.3.1.1. By diseases type
9.3.1.1.1.1. Global market share
9.3.1.1.1.2. Region of operation
9.3.1.2. By treatment type
9.3.1.2.1.1. Global market share
9.3.1.2.1.2. Region of operation
9.4. Allergan Inc.
9.4.1.1. By diseases type
9.4.1.1.1.1. Global market share
9.4.1.1.1.2. Region of operation
9.4.1.2. By treatment type
9.4.1.2.1.1. Global market share
9.4.1.2.1.2. Region of operation
9.5. Bausch & Lomb Incorporated.
9.5.1.1. By diseases type
9.5.1.1.1.1. Global market share
9.5.1.1.1.2. Region of operation
9.5.1.2. By treatment type
9.5.1.2.1.1. Global market share
9.5.1.2.1.2. Area of operation
9.6. Eyegate Pharmaceuticals Inc.
9.6.1.1. By diseases type
9.6.1.1.1.1. Global market share
9.6.1.1.1.2. Region of operation
9.6.1.2. By treatment type
9.6.1.2.1.1. Global market share
9.6.1.2.1.2. Area of operation
9.7. Novartis AG (Alcon Laboratories Inc.)
9.7.1.1. By diseases type
9.7.1.1.1.1. Global market share
9.7.1.1.1.2. Region of operation
9.7.1.2. By treatment type
9.7.1.2.1.1. Global market share
9.7.1.2.1.2. Area of operation
9.8. pSivida Corp.
9.8.1.1. By diseases type
9.8.1.1.1.1. Global market share
9.8.1.1.1.2. Region of operation
9.8.1.2. By treatment type
9.8.1.2.1.1. Global market share
9.8.1.2.1.2. Area of operation
9.9. Regeneron Pharmaceuticals Inc.
9.9.1.1. By diseases type
9.9.1.1.1.1. Global market share
9.9.1.1.1.2. Region of operation
9.9.1.2. By treatment type
9.9.1.2.1.1. Global market share
9.9.1.2.1.2. Area of operation
9.10. Santen Pharmaceutical Co. Ltd.
9.10.1.1. By diseases type
9.10.1.1.1.1. Global market share
9.10.1.1.1.2. Region of operation
9.10.1.2. By treatment type
9.10.1.2.1.1. Global market share
9.10.1.2.1.2. Area of operation
9.11. Valeant Pharmaceuticals International Inc.
9.11.1.1. By diseases type
9.11.1.1.1.1. Global market share
9.11.1.1.1.2. Region of operation
9.11.1.2. By treatment type
9.11.1.2.1.1. Global market share
9.11.1.2.1.2. Area of operation
9.12. Akorn Pvt. Ltd
9.12.1.1. By diseases type
9.12.1.1.1.1. Global market share
9.12.1.1.1.2. Region of operation
9.12.1.2. By treatment type
9.12.1.2.1.1. Global market share
9.12.1.2.1.2. Area of operation
9.13. Roche Ltd
9.13.1.1. By diseases type
9.13.1.1.1.1. Global market share
9.13.1.1.1.2. Region of operation
9.13.1.2. By treatment type
9.13.1.2.1.1. Global market share
9.13.1.2.1.2. Area of operation
9.14. Senju Pharmaceutical Co. Ltd
9.14.1.1. By diseases type
9.14.1.1.1.1. Global market share
9.14.1.1.1.2. Region of operation
9.14.1.2. By treatment type
9.14.1.2.1.1. Global market share
9.14.1.2.1.2. Area of operation
9.15. Bayer HealthCare Pharmaceutical LLC
9.15.1.1. By diseases type
9.15.1.1.1.1. Global market share
9.15.1.1.1.2. Region of operation
9.15.1.2. By treatment type
9.15.1.2.1.1. Global market share
9.15.1.2.1.2. Area of operation
9.16. Pfizer Pharmaceutical company
9.16.1.1. By diseases type
9.16.1.1.1.1. Global market share
9.16.1.1.1.2. Region of operation
9.16.1.2. By treatment type
9.16.1.2.1.1. Global market share
9.16.1.2.1.2. Area of operation
9.17. Cipla Ltd.
9.17.1.1. By diseases type
9.17.1.1.1.1. Global market share
9.17.1.1.1.2. Region of operation
9.17.1.2. By treatment type
9.17.1.2.1.1. Global market share
9.17.1.2.1.2. Area of operation
9.18. Ocular Therapeutix, Inc.
9.18.1.1. By diseases type
9.18.1.1.1.1. Global market share
9.18.1.1.1.2. Region of operation
9.18.1.2. By treatment type
9.18.1.2.1.1. Global market share
9.18.1.2.1.2. Area of operation
9.19. Kala Pharmaceuticals
9.19.1.1. By diseases type
9.19.1.1.1.1. Global market share
9.19.1.1.1.2. Region of operation
9.19.1.2. By treatment type
9.19.1.2.1.1. Global market share
9.19.1.2.1.2. Area of operation
9.20. AxeroVision, Inc.
9.20.1.1. By diseases type
9.20.1.1.1.1. Global market share
9.20.1.1.1.2. Region of operation
9.20.1.2. By treatment type
9.20.1.2.1.1. Global market share
9.20.1.2.1.2. Area of operation
9.21. Myvision Eyeclinic
9.21.1.1. By diseases type
9.21.1.1.1.1. Global market share
9.21.1.1.1.2. Region of operation
9.21.1.2. By treatment type
9.21.1.2.1.1. Global market share
9.21.1.2.1.2. Area of operation
9.22. John Musumeci Optical Pty Ltd
9.22.1.1. By diseases type
9.22.1.1.1.1. Global market share
9.22.1.1.1.2. Region of operation
9.22.1.2. By treatment type
9.22.1.2.1.1. Global market share
9.22.1.2.1.2. Area of operation
  • INQUIRE BEFORE BUYING